Substance Use Disorder Treatment: Global Markets to 2030

PUBLISHED: June 1, 2026

PAGES: 116 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

The global substance use disorder (SUD) treatment market was valued at $11.6 billion in 2025, and it is expected to reach $14.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 4.6% from 2025 to 2030.

The North American substance use disorder (SUD) treatment market was valued at $4.2 billion in 2025, and it is projected to reach $5.4 billion by the end of 2030, at a CAGR of 4.8% from 2025 to 2030.

The APAC substance use disorder (SUD) treatment market was valued at $3 billion in 2025, and it is projected to reach $4 billion by the end of 2030, at a CAGR of 5.6% from 2025 to 2030.

Report Scope

This report presents an in-depth analysis of the global SUD treatment market by conditions, drugs, and geographic markets. BCC Research estimates market data for 2024 (the base year) and 2025 and forecasts values for 2026 through 2030. The report focuses on the major trends, challenges, and opportunities in the market and vendor landscape. It also covers the new products, acquisitions, and collaborations related to the market. The report also analyzes environmental, social, and corporate governance (ESG) developments.

The report concludes with an analysis of the competitive landscape for each condition. There is also a section of profiles of the leading companies.

Report Includes

25 data tables and 57 additional tables
Overview and an analysis of the global market for substance use disorder treatment therapeutics
Analyses of the global market trends, with historic revenue from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
Estimates of the current market size and revenue prospects for the global market, accompanied by a market share analysis by condition (substance abuse), treatment type and region
Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impact of macroeconomic variables
Insights derived from Porter's Five Forces model, as well as global supply chain analyses
Patent review, featuring key granted and published patents
Analysis of the industry structure, including companies' market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the current status and ESG practices of leading companies
Company profiles of major players within the industry, including Indivior PLC, Camurus AB, Alkermes, Dr. Reddy's Laboratories Ltd., and Braeburn Inc.

Product Code: PHM035D

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary
Market Dynamics
Emerging Trends
Analysis by Segment
Analysis by Region
Conclusion

Chapter 2 Market Overview

Substance Use Disorder Overview
Analysis of Macroeconomic Factors
Government Funding and Public Healthcare Budgets
Income Inequality and Socioeconomic Status
Labor Market Dynamics
Global Supply Dynamics and the Macroeconomics of Illicit Markets
Impact of U.S. Tariffs
Porter's Five Forces Analysis
Bargaining Power of Buyers: High
Bargaining Power of Suppliers: Low to Moderate
Threat of New Entrants: Moderate
Threat of Substitutes: Moderate
Industry Rivalry: High

Chapter 3 Market Dynamics

Market Dynamics
Market Drivers
Widespread Global Prevalence of Substance Use Disorders
Proliferation of Illicit Drugs
Increasing Awareness of the Clinical Impact of Substance Use Disorders
Increasing Government and Public Health Interventions
Market Challenges
Low Treatment Penetration Despite High Disease Burden
Stigma and Social Barriers
Market Trends
Shift Toward Long-Acting and Sustained-Release Therapies
Innovation in Drug Development
Expansion of Telemedicine
Digital-Pharmacologic Combination Therapies

Chapter 4 Regulatory Landscape

Overview
U.S.
Key Federal Actors and Their Roles
Europe
European Medicines Agency (EMA)
The European Union Drugs Agency (EUDA)
Japan

Chapter 5 Emerging Technologies and Developments

Emerging Technologies and Developments
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs)
Psychedelics
Clinical Trial Analysis
By Condition Type
By Funder Type
Therapeutic Candidates in Late-Stage Clinical Trials

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Global Substance Use Disorder Treatment Market
Nicotine Use Disorder
Nicotine Replacement Therapy
Varenicline
Others
Opioid Use Disorder
Buprenorphine
Methadone
Naltrexone
Alcohol Use Disorder
Naltrexone
Acamprosate
Others
Geographic Breakdown
Global Substance Use Disorder Treatment Market, by Region
North America
Europe
Asia-Pacific
Middle East and Africa
South America

Chapter 7 Competitive Intelligence

Opioid Use Disorder
Alcohol Use Disorder
Nicotine Use Disorder

Chapter 8 Sustainability in Substance Use Disorder Treatment Market: An ESG Perspective

Introduction to ESG
Key ESG Issues Specific to the Substance Use Disorder Treatment Market
Closing the Treatment Gap
Community Engagement and Stigma Reduction
Carbon Footprint Reduction
Data Transparency and Outcomes Reporting
Concluding Remarks

Chapter 9 Appendix

Methodology
Sources
Abbreviations
Company Profiles
ACHIEVE LIFE SCIENCES INC.
ADIAL PHARMACEUTICALS
ALKERMES
BRAEBURN INC.
CAMURUS AB
DA-PHARMA
DR. REDDY'S LABORATORIES LTD.
ETHYPHARM
H. LUNDBECK A/S
INDIVIOR PLC
KENVUE
LILLY USA LLC.
NFL BIOSCIENCES
OREXO AB (PUBL.)
PAR HEALTH INC.
Emerging Startups/Market Disruptors

Product Code: PHM035D

List of Tables

Summary Table : Global Market for Substance Use Disorder Treatment, by Region, Through 2030
Table 1 : Substance Use Disorders Prevalence for Key Substances in the U.S., 2023
Table 2 : The Substance Use Treatment Gap in the U.S., 2024
Table 3 : Therapeutic Candidates in Phase 3 for Nicotine Use Disorder or Alcohol Use Disorder
Table 4 : Therapeutic Candidates in Phase 2 for Opioid Use Disorder
Table 5 : Therapeutic Candidates in Phase 2 for Alcohol Use Disorder
Table 6 : Therapeutic Candidates in Phase 2 for Nicotine Use Disorder
Table 7 : Industry-Sponsored Therapeutic Candidates in Phase 2 for Cannabis Use Disorder
Table 8 : Industry-Sponsored Therapeutic Candidates in Phase 2 for Methamphetamine Use Disorder
Table 9 : Drug Classes Commonly Associated with Substance-Related Disorders
Table 10 : Global Market for Substance Use Disorder Treatment, by Condition, Through 2030
Table 11 : Global Market for Nicotine Use Disorder Treatment, by Drug Type, Through 2030
Table 12 : NRT Products
Table 13 : Global Market for Opioid Use Disorder Treatment, by Drug Type, Through 2030
Table 14 : FDA-Approved Buprenorphine Medications for Opioid Use Disorder (MOUD)
Table 15 : OUD Medications: An Overview
Table 16 : Global Market for Alcohol Use Disorder Treatment, by Drug Type, Through 2030
Table 17 : Alcohol Use Disorder Medications: An Overview
Table 18 : Global Market for Substance Use Disorder Treatment, by Region, Through 2030
Table 19 : North American Market for Substance Use Disorder Treatment, by Condition, Through 2030
Table 20 : North American Market for Substance Use Disorder Treatment, by Country, Through 2030
Table 21 : Substance Use Among the General Population in Canada, 2023
Table 22 : European Market for Substance Use Disorder Treatment, by Condition, Through 2030
Table 23 : European Market for Substance Use Disorder Treatment, by Country, Through 2030
Table 24 : Share of Adults Who Smoked in 2000 versus 2024 Trends in Prevalence of Tobacco Use Among People Aged 15 Years and Older, by WHO Region
Table 25 : Adult Substance Misuse Treatment Statistics in the U.K., 2023-2024
Table 26 : Asia-Pacific Market for Substance Use Disorder Treatment, by Condition, Through 2030
Table 27 : Asia-Pacific Market for Substance Use Disorder Treatment, by Country, Through 2030
Table 28 : Middle East and African Market for Substance Use Disorder Treatment, by Condition, Through 2030
Table 29 : Share of Population with Alcohol Use Disorder (2021) versus Drug Use Disorder (2021) versus Smoke or Tobacco Users (2022)
Table 30 : South American Market for Substance Use Disorder Treatment, by Condition, Through 2030
Table 31 : Information Sources for this Report
Table 32 : Abbreviations Used in This Report
Table 33 : Achieve Life Sciences Inc.: Company Snapshot
Table 34 : Achieve Life Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 35 : Achieve Life Sciences Inc.: Product Portfolio
Table 36 : Achieve Life Sciences Inc.: News/Key Developments, 2024-2025
Table 37 : Adial Pharmaceuticals: Company Snapshot
Table 38 : Adial Pharmaceuticals: Financial Performance, FY 2023 and 2024
Table 39 : Adial Pharmaceuticals: Product Portfolio
Table 40 : Adial Pharmaceuticals: News/Key Developments, 2025
Table 41 : Alkermes: Company Snapshot
Table 42 : Alkermes: Financial Performance, FY 2023 and 2024
Table 43 : Alkermes: Product Portfolio
Table 44 : Braeburn Inc.: Company Snapshot
Table 45 : Braeburn Inc.: Product Portfolio
Table 46 : Camurus AB: Company Snapshot
Table 47 : Camurus AB: Financial Performance, FY 2023 and 2024
Table 48 : Camurus AB: Product Portfolio
Table 49 : Camurus AB: News/Key Developments, 2025
Table 50 : Da-pharma: Company Snapshot
Table 51 : Da-pharma: Product Portfolio
Table 52 : Dr. Reddy's Laboratories Ltd.: Company Snapshot
Table 53 : Dr. Reddy's Laboratories Ltd.: Financial Performance, FY 2023 and 2024
Table 54 : Dr. Reddy's Laboratories Ltd.: Product Portfolio
Table 55 : Dr. Reddy's Laboratories Ltd.: News/Key Developments, 2025
Table 56 : Ethypharm: Company Snapshot
Table 57 : Ethypharm: Product Portfolio
Table 58 : H. Lundbeck A/S: Company Snapshot
Table 59 : H. Lundbeck A/S: Financial Performance, FY 2023 and 2024
Table 60 : H. Lundbeck A/S: Product Portfolio
Table 61 : Indivior PLC: Company Snapshot
Table 62 : Indivior PLC: Financial Performance, FY 2023 and 2024
Table 63 : Indivior PLC: Product Portfolio
Table 64 : Indivior PLC: News/Key Developments, 2025
Table 65 : Kenvue: Company Snapshot
Table 66 : Kenvue: Financial Performance, FY 2023 and 2024
Table 67 : Kenvue: Product Portfolio
Table 68 : Lilly USA LLC.: Company Snapshot
Table 69 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 70 : Lilly USA LLC.: Product Portfolio
Table 71 : NFL Biosciences: Company Snapshot
Table 72 : NFL Biosciences: Financial Performance, FY 2023 and 2024
Table 73 : NFL Biosciences: Product Portfolio
Table 74 : NFL Biosciences: News/Key Developments, 2025
Table 75 : Orexo AB (Publ.): Company Snapshot
Table 76 : Orexo AB (Publ.): Financial Performance, FY 2023 and 2024
Table 77 : Orexo AB (Publ.): Product Portfolio
Table 78 : Orexo AB (Publ.): News/Key Developments, 2024-2025
Table 79 : Par Health Inc.: Company Snapshot
Table 80 : Par Health Inc.: Product Portfolio
Table 81 : Emerging Startups/Market Disruptors

List of Figures

Summary Figure : Global Market Shares for Substance Use Disorder Treatment, by Region, 2024
Figure 1 : Porter's Five Forces Analysis-Substance Use Disorder Treatment Industry
Figure 2 : Market Dynamics of Substance Use Disorder Treatment
Figure 3 : Active Clinical Trials of Substance Use Disorders, by Condition, 2025
Figure 4 : Active Clinical Trials of Substance Use Disorders, by Funder Type, 2025
Figure 5 : Global Market Shares for Substance Use Disorder Treatment, by Condition, 2024
Figure 6 : Global Market Shares for Nicotine Use Disorder Treatment, by Drug Type, 2024
Figure 7 : Global Market Shares for Opioid Use Disorder Treatment, by Drug Type, 2024
Figure 8 : Global Market Shares for Alcohol Use Disorder Treatment, by Drug Type, 2024
Figure 9 : Global Market Shares for Substance Use Disorder Treatment, by Region, 2024
Figure 10 : North American Market Shares for Substance Use Disorder Treatment, by Condition, 2024
Figure 11 : North American Market Shares for Substance Use Disorder Treatment, by Country, 2024
Figure 12 : Number of Americans Aged 12 or Older Using Cigarette or Nicotine Vaping Products
Figure 13 : European Market Shares for Substance Use Disorder Treatment, by Condition, 2024
Figure 14 : European Market Shares for Substance Use Disorder Treatment, by Country, 2024
Figure 15 : People in Opioid Agonist Treatment in the EU in 2023, by Type of Medication
Figure 16 : Total Number of Adults Receiving Treatment for Drugs and/or Alcohol in England
Figure 17 : Asia-Pacific Market Shares for Substance Use Disorder Treatment, by Condition, 2024
Figure 18 : Asia-Pacific Market Shares for Substance Use Disorder Treatment, by Country, 2024
Figure 19 : Middle East and African Market Shares for Substance Use Disorder Treatment, by Condition, 2024
Figure 20 : South American Market Shares for Substance Use Disorder Treatment, by Condition, 2024
Figure 21 : Global Market Shares for Opioid Use Disorder Treatment Market, by Company, 2024
Figure 22 : ALKERMES: Revenue Shares, by Business Unit, FY 2024
Figure 23 : ALKERMES: Revenue Shares, by Country/Region, FY 2024
Figure 24 : Camurus AB: Revenue Shares, by Business Unit, FY 2024
Figure 25 : Camurus AB: Revenue Shares, by Country/Region, FY 2024
Figure 26 : Dr. Reddy's Laboratories Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 27 : Dr. Reddy's Laboratories Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 28 : H. Lundbeck A/S: Revenue Shares, by Business Unit, FY 2024
Figure 29 : H. Lundbeck A/S: Revenue Shares, by Country/Region, FY 2024
Figure 30 : Indivior PLC: Revenue Shares, by Business Unit, FY 2024
Figure 31 : Indivior PLC: Revenue Shares, by Country/Region, FY 2024
Figure 32 : KENVUE: Revenue Shares, by Business Unit, FY 2024
Figure 33 : KENVUE: Revenue Shares, by Country/Region, FY 2024
Figure 34 : Lilly USA LLC.: Revenue Shares, by Business Unit, FY 2024
Figure 35 : Lilly USA LLC.: Revenue Shares, by Country/Region, FY 2024
Figure 36 : Orexo AB (Publ.): Revenue Shares, by Business Unit, FY 2024
Figure 37 : Orexo AB (Publ.): Revenue Shares, by Country/Region, FY 2024